Phase II study of amrubicin combined with carboplatin for unresectable invasive thymoma or thymic carcinoma

Phase II study of amrubicin combined with carboplatin for unresectable invasive thymoma or thymic carcinoma - Amrubicin and carboplatin for invasive thymoma/thymic carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002619

Enrollment

Registered

2010-03-31

Start date

2008-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thymoma/Thymic carcinoma

Interventions

Amrubicin and carboplatin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically proven thymoma or thymic carcinoma 2. ECOG performance status 0-2 3. Adequate organ function 4. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Severe co-morbidities 2. Symptomatic brain metastasis 3. Massive effusion that require drainage 4. Pregnant woman

Design outcomes

Primary

Measure	Time frame
Response rate	—

Countries

Japan

Contacts

Public ContactAkira Inoue

Tohoku University Hospital Department of Respiratory Medicine

akinoue@idac.tohoku.ac.jp+81-22-717-8539

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026